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Crystal structure of quinolinic acid phosphoribosyltransferase
from Mycobacterium tuberculosis: a potential TB drug target
Vivek Sharma1, Charles Grubmeyer2 and James C Sacchettini1*
Background: Mycobacterium tuberculosis is the single most deadly human
pathogen and is responsible for nearly three million deaths every year. Recent
elucidation of the mode of action of isoniazid, a frontline antimycobacterial drug,
suggests that NAD metabolism is extremely critical for this microorganism.
M. tuberculosis depends solely on the de novo pathway to meet its NAD
demand. Quinolinic acid phosphoribosyltransferase (QAPRTase), a key enzyme
in the de novo biosynthesis of NAD, provides an attractive target for designing
novel antitubercular drugs.
Results: The X-ray crystal structure of the M. tuberculosis QAPRTase
apoenzyme has been determined by multiple isomorphous replacement at 2.4 Å
resolution. Structures of the enzyme have also been solved in complex with the
substrate quinolinic acid (QA), the inhibitory QA analog phthalic acid (PA), the
product nicotinate mononucleotide (NAMN), and as a ternary complex with PA
and a substrate analog, 5-phosphoribosyl-1-(β-methylene)pyrophosphate
(PRPCP). The structure of the nonproductive QAPRTase–PA–PRPCP
Michaelis complex reveals a 5-phosphoribosyl-1-pyrophosphate-binding site
that is different from the one observed in type I phosphoribosyltransferases
(PRTases). The type II PRTase active site of QAPRTase undergoes
conformational changes that appear to be important in determining substrate
specificity and eliciting productive catalysis.
Conclusions: QAPRTase is the only known representative of the type II
PRTase fold, an unusual α/β barrel, and appears to represent convergent
evolution for PRTase catalysis. The active site of type II PRTase bears little
resemblance to the better known type I enzymes.
Introduction
Quinolinic acid phosphoribosyl transferase (QAPRTase;
EC 2.4.2.19), encoded by the nadC gene, is a key enzyme
in de novo biosynthesis of NAD [1]. The enzyme carries
out the Mg2+-dependent transfer of the phosphoribosyl
moiety from 5-phosphoribosyl-1-pyrophosphate (PRPP)
to quinolinic acid (QA) yielding nicotinic acid mono-
nucleotide (NAMN), pyrophosphate and CO2 (Figure 1).
In eukaryotes, QA is largely produced by tryptophan
degradation, whereas in prokaryotes it is produced from
L-aspartate and dihydroxyacetone phosphate by products
of the nadB (L-aspartate oxidase) and nadA (quinolinate
synthase) genes [2]. In Mycobacterium tuberculosis, the three
genes encoding the enzymes involved in the de novo
biosynthesis of NAMN are part of a single operon (nadABC)
[3]. In bacteria, the nad operon is transcriptionally regu-
lated by a repressor encoded by the nadR gene in
response to intracellular levels of nicotinamide mono-
nucleotide (NMN) [4]. Alternatively, NAMN can be pro-
duced by a salvage pathway that proceeds via the
phosphoribosylation of nicotinic acid (NA), generated by
the degradation of NAD; this reaction is catalyzed by the
enzyme nicotinate phosphoribosyltransferase (NAPRTase)
[5]. Despite the similarity between their enzymatic reac-
tions, QAPRTase and NAPRTase exhibit exclusive speci-
ficity for their respective substrates [6,7]. In M. tuberculosis,
unlike most organisms, the salvage pathway appears to be
disrupted. This is proposed to be a consequence of the
lack of detectable NAPRTase activity and results in
secretion of NA produced by degradation of NAD [1].
Relying entirely on the de novo pathway for its NAD
requirements, M. tuberculosis should be extremely vulner-
able to drugs targeted against QAPRTase.
Several lines of evidence suggest high susceptibility of
M. tuberculosis towards drugs that modify NADH or inhibit
its biosynthesis. We have recently demonstrated that iso-
niazid, a first line antimycobacterial drug, acts by produc-
ing isonicotinylated NADH which in turn inhibits enoyl
ACP reductase (InhA), an enzyme involved in mycolate
synthesis [8]. Resistance to isoniazid can, in fact, be con-
ferred by modulation of NADH levels [9]. 
Phosphoribosyltransferases (PRTases) constitute a group
of enzymes that participate in the biosynthesis of pyrimi-
dine, purine and pyridine nucleotides, as well as the
Addresses:  1Department of Biochemistry and
Biophysics, Texas A&M University, College Station,
TX 77843, USA and 2Department of Biochemistry,
Temple University School of Medicine and Fels
Institute for Cancer Research, Philadelphia, PA
19140, USA.
*Corresponding author.
E-mail:  sacchett@seabass.tamu.edu
Key words: NAD biosynthesis,
phosphoribosyltransferase, PRPP, QAPRTase,
quinolinate
Received:  13 August 1998
Revisions requested:  17 September 1998
Revisions received:  5 October 1998
Accepted:  14 October 1998
Structure 15 December 1998, 6:1587–1599
http://biomednet.com/elecref/0969212600601587
© Current Biology Ltd ISSN 0969-2126
Research Article 1587
amino acids histidine and tryptophan [10]. The nucleotide
formation chemistry involves inversion of stereochemistry
at the anomeric ribose C1, and has been proposed to
proceed via a transition state with considerable oxocarbo-
nium character at the C1–O4 of ribose [11]. The PRTases
are currently divided into two structurally distinct groups:
type I and type II. The crystal structures of several type I
PRTases are now known [12–19] and include structures of
orotate phosphoribosyltransferase (OPRTase), hypoxan-
thine guanine phosphoribosyltransferase (HGPRTase),
glutamine phosphoribosyl amidotransferase (GPATase)
and uracil phosphoribosyltransferase (UPRTase), all of
which contain a conserved 13-residue PRPP-binding motif.
All type I enzymes possess a fold composed of a central
parallel five-stranded β sheet surrounded by α helices.
QAPRTase, a type II PRTase, has been studied less
extensively and represents the only known example of
this class [19]. The type II PRTase fold consists of an
N-terminal four-stranded open face β-sandwich domain
and a C-terminal α/β-barrel domain. Despite their dis-
tinct structural folds, type I and II PRTases carry out
very similar enzymatic reactions involving the donation
of a ribose-5-phosphate from PRPP to a nitrogenous base
to form nucleotide and pyrophosphate as products. The
PRTases thus represent an elegant example of conver-
gent evolution towards a similar enzymatic activity. Further
structure/function comparisons of these proteins have
been limited by difficulties in obtaining structural infor-
mation about their active sites in the catalytic stage,
owing to both the highly unstable nature of PRPP and
the highly reactive nature of the intermediate. Some of
these problems were overcome by turning over orotate
monophosphate (OMP) and pyrophosphate to form PRPP
and orotate in the crystalline enzyme OPRTase [10] or,
more recently, by using a stable carbocyclic analog of
PRPP in the structure of GPATase [20]. In the latter
case, a major conformational change involving movement
of a peptide loop to occlude the active site from solvent
is essential for catalysis.
Two crystal structures of Salmonella typhimurium QAPRTase
(St-QAPRTase), in complex with QA and NAMN, were
recently determined at 2.8 Å and 3.0 Å resolution,
respectively [19]. Fundamental problems with the crystal
form limited higher resolution with the S. typhimurium
enzyme, and led us to examine crystals of the enzyme
from other sources. In this paper we report a high-resolu-
tion structure of the apoenzyme from M. tuberculosis as
well as the structures of three binary complexes (with
substrate QA, product NAMN and inhibitor PA) and a
ternary complex (with bound PA and a stable analog of
PRPP, PRPCP). The availability of the structures of
QAPRTase with and without its substrates and products
provides a detailed perspective for the active-site inter-
actions in pre-catalytic, catalytic and post-catalytic stages
of the enzyme. In addition, the high-resolution structure
of M. tuberculosis QAPRTase (Mt-QAPRTase) reveals a
number of features that could be exploited to design
novel antimycobacterials.
Results and discussion
The QAPRTase structure
Mt-QAPRTase is a homodimer with each 29 kDa subunit
consisting of 285 amino acids. Crystals of the apo
Mt-QAPRTase diffracted to a resolution of 2.4 Å. The
asymmetric unit of the crystal, space group P31, contains
three dimers, which are related by a threefold noncrystal-
lographic symmetry (NCS). Attempts to solve the struc-
ture by molecular replacement using the St-QAPRTase
structure as a search model failed, and the structure was
solved by multiple isomorphous replacement (MIR),
relying on Hg, Pt and Sm soaked crystals to obtain heavy-
atom derivatives (Table 1). The initial electron-density
maps were improved using NCS averaging and phase
refinement, and NCS constraints were applied in the early
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Figure 1
Schematic representation of the reaction catalyzed by QAPRTase.
(The figure was drawn using the program Chemdraw Plus version 3.1
[Cambridge Scientific Computing].)
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Structure
stages of model building and refinement. The final model
had greater than 93% of the residues in the most favored
regions of the Ramachandran plot, with the remaining 7%
in additional allowed regions.
A single subunit of Mt-QAPRTase comprises 11 β strands
and ten α helices arranged into two structural domains
(Figure 2a). The N-terminal open-face β-sandwich domain
is composed of a four-stranded (β1, β2, β3 and β11) anti-
parallel β sheet stacked against helices α1, α2, α3 and part
of α4. The strands β1 and β2 are followed by two short
β strands (β1a and β2a) forming a small two-stranded
antiparallel β sheet. The C-terminal domain is an α/β-barrel
structure consisting of the remaining seven β strands (β4,
β5, β6, β7, β8, β9 and β10) and six α helices (α4, α5, α6, α7,
α8 and α9) arranged in (αβ)2β(αβ)4 topology. In addition, a
short helix (α6a) is present after strand β6 and before
helix α6. The connection between the two domains is
through the longest (33 residues) helix α4 and helix α10.
The Mt-QAPRTase dimer is formed by a twofold symmetry
that places the N-terminal domain of one subunit next to
the C-terminal domain of the other. The two active sites are
located at the interfaces between the α/β barrel of one
subunit and the β sandwich of the second subunit and are
composed of residues from both subunits. (The residues
and structural elements of the second subunit are desig-
nated with a prime in the text and figures.)
As shown in Figure 2b, the three dimers in the asymmet-
ric unit are related by an approximate threefold noncrys-
tallographic symmetry (κ1 = 119.6, κ2 = 240.1) parallel to
the crystallographic threefold screw axis. In addition, two
subunits in each of the three dimers are related by a non-
crystallographic twofold axis perpendicular to the non-
crystallographic threefold axis. Although Mt-QAPRTase
appears as a dimer during gel filtration under physiolog-
ical conditions, the hexameric form may result at the
high protein concentrations and ionic strengths used in
crystallization. Interestingly, hexameric QAPRTases have
been reported from mammals such as hog [21], rat [22]
and human [23]. The interface between dimers is largely
solvent accessible and hydrated in character. Stacking
interactions between the sidechains of Arg48 and Trp227
form the major protein–protein contact at this interface.
The three dimers of QAPRTase in the asymmetric unit
each have dimensions of 45 Å × 67 Å × 75 Å. The dimer
interfaces bury 3038 Å2 (dimer A–B), 3518 Å2 (dimer C–D)
and 2861 Å2 (dimer E–F) of protein surface, which repre-
sents approximately 20% of the total accessible surface
area of each subunit. The root mean square deviation
(rmsd) between corresponding Cα atoms of two subunits
in a given dimer is 0.46 Å; this value varies from 0.61 Å to
0.64 Å for subunits in different dimers. Comparison of
Mt-QAPRTase and St-QAPRTase, which share 38%
sequence identity, reveals that the structures of the two
proteins are mostly similar, with an rmsd of 1.5 Å for all
corresponding Cα atoms.
The QA-binding site of Mt-QAPRTase is a deep, yet
solvent accessible, pocket located at the center of the α/β
barrel with a highly positive electrostatic surface [19].
This surface is composed of three arginine residues
(Arg139, Arg162 and Arg105′), two lysine residues (Lys140
and Lys172) and one histidine residue (His161). All of
these residues are highly conserved among QAPRTases
(Figure 3) and adopt similar conformations in the struc-
tures of Mt-QAPRTase and St-QAPRTase. Leu220 of
Mt-QAPRTase, replacing Met233 in St-QAPRTase, is
the only residue to differ in the QA-binding sites of the
two structures. Relatively more variation is observed in
the 5-phosphate-binding site, where Gly250 and His274
in Mt-QAPRTase replace the residues Asn260 and Lys274
of St-QAPRTase, respectively. 
In the Mt-QAPRTase apoenzyme structure, the QA-
binding site is occupied by a solvent molecule, which
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Table 1 
Summary of heavy-atom derivative data and binding sites.
Native Hg acetate SmCl PtCl4
Resolution (Å) 2.3 2.5 2.8 2.7
Unique reflections 68,930 53,794 39,749 43,978
Redundancy 2.82 3.04 3.44 3.28
Completeness (%) 94.9 95.6 99.0 97.9
Rsym (%)* 7.6 7.2 7.8 7.3
Riso (%)† 10.4 10.7 13.3
Number of sites 6 6 6
Phasing power‡ 1.39 1.49 1.34
Binding-site residues Cys198 Asp222, Glu201 Met244, Tyr266
*Rsym = (Σ|I–〈I〉|)/ΣI, where I are observed intensities and 〈I〉 are average intensities for redundant measurements. †Riso = (Σ|FPH–FP|)/ΣFP, where FP
and FPH are the observed native and derivative structure-factor amplitudes, respectively. ‡Phasing power = Σ|FH(calc)|/ Σ|E|, where FH is the structure
factor of the heavy atoms and E is the lack of closure error (E = |FPH(obs)|–|FPH(calc)|).
interacts with the sidechain atoms of residues Arg139 and
Arg162 (Figure 4a). A sulfate ion is present in the phos-
phate-binding site of the apoenzyme and in the enzyme
with bound QA and PA. The interaction with sulfate is
mediated by hydrogen bonds with the backbone amides
of residues Gly270 and Ala271, the backbone carbonyl of
Gly249 and the sidechain atoms of Lys140 and His274.
The sulfate ion is also hydrogen bonded to a water mol-
ecule, which in turn forms hydrogen bonds with the back-
bone amide of Gly249 and the backbone carbonyl of
Ala268. The ability of NAMN and PRPP to displace this
tightly bound sulfate ion, a constituent of the purification
and crystallization buffers, is critical for obtaining their
complexes with QAPRTase, as discussed below. 
The QA-binding site
In order to explore the structural basis of the catalytic mech-
anism and to characterize any substrate-induced move-
ments in the catalytic site, crystals of Mt-QAPRTase were
soaked with the substrate QA or a substrate analog, phthalic
acid (PA). Difference maps clearly revealed the position
of both QA and PA. The orientation of QA and PA is
essentially identical in their respective complexes with
QAPRTase. This is not surprising because PA, a strong
competitive inhibitor with respect to QA, has been pro-
posed to bind to the QA-binding site of QAPRTase [24].
The interactions of QA with QAPRTase are shown in
Figure 4a. QA buries about 160 Å2 of the solvent accessible
protein surface, of which 62% is hydrophobic and 38% is
polar. The C3 carboxylate group of QA forms hydrogen
bonds with the sidechain atoms Nε and Nη of Arg162 and
Nε of Arg139, whereas the C2 carboxylate group is within
hydrogen-bonding distance of the mainchain NH of Arg139,
the sidechain of Arg105′ and the sidechain Nη of Lys172. In
addition, the sidechains of the residues Thr138, His161,
Leu170 and Leu220 are within van der Waals distance of
the substrate. PA in the ternary complex (Figure 4b) and
the nicotinate ring of NAMN (Figure 4c) occupy the QA-
binding site in a similar fashion. Several binding-site
residues, including Lys172 and His175, are 4–5 Å closer to
the QA substrate in Mt-QAPRTase than their counterparts
in the St-QAPRTase–QA complex structure.
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Figure 2
Ribbon drawings showing the overall
structure of Mt-QAPRTase. (a) Stereoview of
the QAPRTase dimer. For one of the
monomers the α/β barrel is shown with
helices in red and strands in blue, and the
open face of the β sandwich is shown with
purple helices and yellow strands; the second
monomer is shown in cyan. (b) Ribbon
diagram of the QAPRTase hexamer in the
asymmetric unit; each subunit is shown in a
different color. (The figures were drawn using
the programs MOLSCRIPT [33] and
RASTER3D [34].)
Binding to QA is accompanied by substantial structural
changes in the active site of QAPRTase. These include
reorientation of the sidechains of binding-site residues
His161, Leu170, Lys172 and Leu220 (Figure 4a), which
imparts structural complementarity between the enzyme
and the substrate. The structures of QAPRTase in the
QA-bound and apo form exhibit an overall rmsd of 0.51 Å
between corresponding Cα atoms, a difference which is
on the same scale as that observed between subunits in
the asymmetric unit. However, in two regions, residues
169–196 (β6, α6A and α6) and residues 28′–36′ (helix α2′),
the deviation for all atoms is more than 1 Å (Figure 5).
Omission of these two regions decreases the overall rmsd
to 0.35 Å for QA-bound versus apo QAPRTase. These
structural changes stem from the conformational flexibility
in the sidechain of residue Lys172, which orients in an
altogether different fashion in the two structures. In the
structure of the apoenzyme, the Nε atom of Lys172 hydro-
gen bonds with the sidechains of residues Asn174 and
Glu104′, whereas in the QA-bound structure it orients
towards the C2 carboxylate of QA. This results in a 5 Å
movement of the Lys172 sidechain Nε atom and a 2 Å
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Figure 3
Sequence alignment of the QAPRTase
homologs. Conserved residues are shown as
white letters on a black background. The
secondary structure elements of
Mt-QAPRTase are shown above the
alignment; α helices are represented as
rectangles and β strands as arrows.
Sequences of QAPRTase from seven
organisms are shown: Mycobacterium
tuberculosis, Mycobacterium leprae, Bacillus
subtilis, Escherichia coli, Saccharomyces
cerevisiae, Salmonella typhi and Homo
sapiens. (Sequences were aligned using the
program CLUSTALW version 1.6 [35].)
α1 α2 β1
β5
β11
β1a β2 β2a β3α3
β4α4 α5
β7β6 α6a α6 α7
β10β9β8 α8 α9 α10
               10           20      30        40
M. tuberculosis            MGLSDWELAAARAAIARGLDEDLRYGPDVT   TLATVPASATTTASLV
M. leprae                   MLSDCEFDAARDTIRRALHEDLRYGLDIT   TQATVPAGTVVTGSMV
B. subtilis                     MNHLQLKKLLNHFFLEDIGTGDLTS     QSIFGEQSCEAEIV
E. coli         PPRRYNPDTRRDELLERINLDIPGAVAQALREDLGGTVDANNDITAKLLPENSRSHATVI
S. cerevisiae           MPVYEHLLPVNGAWRQDVTNWLSEDVPSFDFGG      YVVGSDLKEANLY
S. typhi        PPRRYNPDDRRDALLERINLDIPAAVAQALREDLGGEVDAGNDITAQLLPADTQAHATVI
H. sapiens            MDAEGLALLLPP VTLAALVDSWLREDCPGLNYAA      LVSGAGPSQAALW
  50              60         70   80              90       100
M. tuberculosis TREAGVVAGLDVALLTLNEVLGTNGYRVLDRVEDGARVPPGEA      LMTLEAQTRGL
M. leprae       PREPGVIAGVDVALLVLDEVFGVDGYRVLYRVEDGARLQSGQP      LLTVQAAARGL
B. subtilis     AKSEGIFAGAAIIKEGFSLLDEN  VQSILHKKDGDMLHKGEV      IAELHGPAAAL
E. coli         TRENGVFCGKRWVEEVFIQLAG DDVTIIWHVDDGDVINANQS      LFELEGPSRVL
S. typhi        TREDGVFCGKRWVEEVFIQLAG DDVRLTWHVDDGDAIHANQT      VFELNGPARVL
S. cerevisiae   CKQDGMLCGVPFAQEVFNQCEL   Q VEWLFKEGSFLEPSKNDSGKIVVAKITGPAKNI
H. sapiens      AKSPGVLAGQPFFDAIFTQLNC   Q VSWFLPEGSKLVPVAR      VAEVRGPAHCL
 110             120        130       140  150
M. tuberculosis LTAERTMLNLVGHLSGIATATAAWVDAVRGT  KAKIRDTRKTLPGLRALQKYAVRTGGG
M. leprae       LTAERTMLNLVCHMSGIATVTVAWVDAVRGT  KAKIRDTRKTLPGLRALQKYAVRVGGG
B. subtilis     LSGERVVLNLIQRLSGIATMTREAVRCLDDE  QIKICDTRKTTPGLRMLEKYAVRAGGG
E. coli         LTGEPTALNFVQTLSGVASKVRHYVELLEGT  NTQLLDTRKTLPGLRSALKYAVLCGGG
S. typhi        LTGERTALNFVQTLSGVASEVRRYVGLLAGT  QTQLLDTRKTLPGLRTALKYAVLCGGG
S. cerevisiae   LLAERTALNILSRSSGIATASHKIISLARSTGYKGTIAGTRKTTPGLRRLEKYSMLVGGC
H. sapiens      LLGERVALNTLARCSGIASAAAAAVEAARGAGWTGHVAGTRKTTPGFRLVEKYGLLVGGA
            160       170  180             190          200     210
M. tuberculosis VNHRLGLGDAALIKDNHVAAAGSVVDALRAVRNAAP DLPCEVEVDSLEQLDAVLPEKPE
M. leprae       VNHRLGLGDTALIKDNHVAAVGSVVDALRAVRAAAP ELPCEVEVDSLEQLDAMLAEEPE
B. subtilis     YNHRFGLYDGIMIKDNHIAACGSILEACKKARQAAGHMVNIEVEIETEEQLREAIAAGAD
E. coli         ANHRLGLSDAFLIKENHIIASGSVRQAVEKASWLHP DAPVEVEVENLEELDEALKAGAD
S. typhi        ANHRLGLTDAFLIKENHIIASGSVRQAVEKAFWLHP DVPVEVEVENLDELDDALKAGAD
S. cerevisiae   DTHRYDLSSMVMLKDNHIWATGSITNAVKNARAVCGFAVKIEVECLSEDEATEAIEAGAD
H. sapiens      ASHRYDLGGLVMLKDNHVVPPGGVEKAVRAARQAADFALKVEVECSSLQEVVQAAEAGAD
               220          230     240        250  260             270
M. tuberculosis LILLDNFAVWQTQTAVQRRDSRAP   TVMLESSGGLSLQTAATYAETGVDYLAVGALTH
M. leprae       LILLDNFPVWQTQVAVQRRDIRAP   TVLLESSGGLSLENAAIYAGTGVDYLAVGALTH
B. subtilis     VIMFDNCPPDTVRHFAKLTPAN      IKTEASGGITLESLPAFKGTGVNYISLGFLTH
E. coli         IIMLDNFETEQMREAVKRTNG      KALLEVSGNVTDKTLREFAETGVDFISVGALTK
S. typhi        IIMLDNFNTDQMREAVKRVNG      QARLEVSGNVTAETLREFAETGVDFISVGALTK
S. cerevisiae   VIMLDNFKGDGLKMCAQSLKNKWNGKKHFLLECSGGLNLDNLEEYLCDDIDIYSTSSIHQ
H. sapiens      LVLLDNFKPEELHPTATALKAQFPS   VAVEASGGITLDNLPQFCGPHIDVISMGMLTQ
      280
M. tuberculosis SVRVLDIGLDM
M. leprae       SVRILDIGLDL
B. subtilis     SVKSLDI
E. coli         HVQALDLSMRFR
S. typhi        HVRALDLSMRFC
S. cerevisiae   GTPVIDFSLKLAH
H. sapiens      AVPALDFSLKLFAKEVAPVPKIH
Structure
displacement of its Cα atom. An additional water-medi-
ated interaction with the sidechain carboxylate of Glu201
appears to further stabilize the new conformation of Lys172.
Binding to QAPRTase buries 88% of the QA surface, 12%
being contributed by the movement of Lys172. The
enzyme conformational changes are retained in the
QAPRTase–PA–PRPPCP ternary complex and lacking in
the NAMN–complex, consistent with the role of the
C2 carboxylate in inducing them.
The alteration in the conformation of Lys172 on QA
binding has several implications for the specificity and
mechanism of the QAPRTase reaction. The interaction
of Lys172 with the negatively charged C2 substituent
appears to determine the specificity of QAPRTase for
QA. NA, which lacks the C2 carboxylate, would not
induce the Lys172-mediated conformational change and
therefore would not act as a substrate. Secondly, these
conformational changes appear to facilitate PRPP binding
and the subsequent reaction, as is evident from the struc-
ture of the ternary complex described below. Further-
more, Lys172 may have a critical role in decarboxylation
of the QA mononucleotide intermediate by stabilizing
the charge at the C2 position. Finally, the lack of any
1592 Structure 1998, Vol 6 No 12
Figure 4
Stereoviews of the active-site residues of
QAPRTase. (a) Superimposition of the active
sites in the apoenzyme and QAPRTase–QA
complex structures. Carbon atoms are
depicted in gray (apoenzyme), green (QA-
bound enzyme) or cyan (QA); nitrogen atoms
are shown in blue and oxygen atoms in red.
For the QAPRTase–QA complex, only
residues that undergo substrate-induced
conformational changes are shown. (b) The
active site of the ternary complex of
QAPRTase with bound PA and PRPCP.
Carbon atoms are shown in cyan (PA) and
yellow (PRPCP). (c) NAMN (green carbon
atoms) bound to the QAPRTase active site.
(Figures were drawn using the program
SPOCK developed by JA Christopher at
Texas A&M University.)
interaction at the C2 position would facilitate the release
of NAMN from QAPRTase.
Binding of NAMN to QAPRTase
Although the 2.65 Å resolution difference electron-density
map for the QAPRTase–NAMN complex showed discon-
tinuous density for NAMN, sixfold NCS averaging of the
map improved the density considerably with a peak of five
standard deviations clearly resembling the expected elec-
tron density for NAMN (Figure 6). NAMN adopts a con-
formation such that the nicotinate ring and 5-phosphate
occupy positions very similar to those of the QA and sulfate,
respectively, in the QAPRTase–QA complex (Figure 4c).
Moreover, the binding and conformation of NAMN in
complex with Mt-QAPRTase was nearly identical to that
seen in St-QAPRTase [19]. The ribose hydroxyl group
oxygen atoms of NAMN are within hydrogen-bonding
distance of Asp222, Glu201, Gly249, Ser248 and Gly270.
Oxygen atoms of the phosphate group hydrogen bond
with residues Gly270, Ala271, His274 and Lys140. The
C3 carboxylate provides the only hydrogen-bonding inter-
actions for the nicotinate ring with the protein (to the
sidechains of residues His161 and Arg162). The lack of a
C2 carboxylate and a planar geometry at the positively
charged N1 atom results in the movement of the pyrimi-
dine ring by 1 Å relative to the QAPRTase–QA complex.
The overall conformation of the active site appears to be
more similar to that of the apoenzyme, and the conforma-
tional changes observed in the QAPRTase–QA complex
are absent in the QAPRTase–NAMN complex.
The QAPRTase–PA–PRPCP ternary complex
Formation of a ternary complex of QAPRTase with QA
and PRPP is a prerequisite for the enzymatic phospho-
ribosylation of QA. In the presence of Mg2+ ion, which is
required for PRPP binding as well as catalysis [24], this
complex would quickly turn over by formation of a N1–C1
bond between the two substrates to form the product
NAMN. Substituting QA with PA, which has a carbon
atom instead of the nucleophilic N1 atom, allows the for-
mation of a nonproductive ternary Michaelis complex.
Such a complex is obtained by producing the crystals in
crystallization buffer containing 5 mM each of PA, PRPCP
(a stable analog of PRPP [25]) and MnCl2. To counter the
lability of PRPCP in solution, the crystals were soaked
overnight in the same solution prior to data collection. 
For each of the six protein subunits in the asymmetric unit
of the QAPRTase–PA–PRPCP complex, two regions of
electron density were observed in the difference Fourier
electron-density map. Sixfold NCS averaging of the map
allowed unambiguous positioning of the two substrates.
The first peak of density corresponds to that of PA, which
binds in a conformation identical to that seen in its binary
complex with QAPRTase. The second region of positive
electron density is located in the active site at the interface
of the two subunits. A molecule of α-PRPCP in the C3-exo
conformation and two Mn2+ ions fitted into this region of
the electron-density map contoured at five standard devia-
tions (Figure 6). One divalent metal ion is coordinated by
two ribose hydroxyl groups (OH2 and OH3), two
pyrophosphate oxygens (O1 and O1B) and two water mol-
ecules, while the other is coordinated by two PRPCP
oxygens (O1A and O3B) and four water molecules. The
complex of highly acidic PRPP substrate with hydrated
divalent metal ions results in charges complementary to
those on the inner surface of the active-site cavity
(Figure 7). Five basic and four acidic residues lining the
cavity impart opposite electrostatic potential to the two
faces of the PRPP-binding site. Six of these residues
(Lys140, Lys172, Asp173, Glu201, Asp222 and His274) are
contributed by the α/β barrel of one subunit, while the
remaining three (Arg48′, Arg105′ and Asp280′) are a part of
the open-face β-sandwich domain of the other subunit.
The interactions of QAPRTase with PA and PRPCP in
the refined structure are shown in Figure 4b. The
PRPCP–(Mn2+)2–(H2O)6 complex buries 725 Å2 (69% polar
and 31% nonpolar) of accessible surface of the protein and
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Figure 5
Substrate-induced conformational changes in
QAPRTase. Stereoview ribbon representation
of the ternary complex of the enzyme showing
the location of two substrate analogs, PA and
PRPCP, in the fold. The color scheme is the
same as for one monomer in Figure 2a. The
conformations of helices α6A and α2′ in the
apoenzyme are superimposed (shown in
green). The orientation of the Lys172
sidechain in both of the conformers is shown.
The sidechain amine of Lys172 interacts with
the C2 carboxylate of PA (or QA) in the
substrate-bound form and with Glu104′ in the
unliganded or NAMN-bound form. (The figure
was created using the program SETOR [36].)
there are 25 hydrogen bonds and salt bridges formed
between the protein and the substrate (Figure 8). The
5-phosphate group of PRPCP occupies a position nearly
identical to that of the sulfate ion in apo QAPRTase and
QAPRTase–QA or the phosphate in QAPRTase–NAMN.
The 5-phosphate interacts with the backbone amide of the
residue Gly270, the backbone carbonyl of Gly249 and the
sidechains of residues Lys140 and His274. Two water mol-
ecules mediate additional interactions for the 5-phosphate
with residues Ala268 and Ala271. The hydroxyl groups of
the ribose ring make hydrogen bonds with the sidechains
of Glu201, Asp222 and Lys172. The pyrophosphate of
PRPCP is within hydrogen-bonding distance of Arg105′,
Arg48′, Lys140, Asp222 and Asp173. The water molecules
of the dihydrated metal ion form hydrogen bonds with
Asp173, Asp222 and Glu201, whereas that of the tetra-
hydrated metal ion hydrogen bonds to Asp280′, Arg48′, an
ordered water molecule and the OH3 of the ribose.
Comparison of PRPCP and NAMN in the QAPRTase
binding site (Figure 4b and 4c) shows that the two com-
plexes differ substantially with respect to the position of
the common phosphoribosyl moiety. In both cases the
5-phosphate is located in the phosphate-binding site and
forms an equal number of hydrogen bonds with the
protein atoms. At the ribose group, however, there is a
large difference in position between the substrate and the
product. In comparison to NAMN, the ribose ring of
PRPCP is displaced across the binding cavity by a rotation
of almost 90° (Figure 6). This rotation may be guided by a
repulsion of the positively charged oxycarbonium interme-
diate by the large positive electrostatic potential of Lys140
and divalent metal ion, and a simultaneous attraction
towards the acidic QA. The interactions with OH3 and
5-phosphate, which along with the C2 and C3 of ribose
occupy identical positions in the two structures, appear to
hinge the phosphoribosyl moiety on the protein during
rotation. A large movement (~2.6 Å) in the anomeric C1
atom accompanies the inversion of its stereochemistry.
Comparison with type I PRTases
Despite catalyzing enzymatically similar reactions, the
α/β-barrel fold of QAPRTase shows no resemblance to the
type I PRTases. OPRTase, HGPRTase, GPATase and
UPRTase all have the type I fold and, therefore, despite
having little sequence homology appear to have
descended from a common ancestor. QAPRTase, the only
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Figure 7
Surface representation of the active site of QAPRTase. PA (yellow) and
PRPCP (green) are shown in stick representation. The molecular surface
of the protein is colored according to the electrostatic potential due to
the protein sidechain atoms. (The figure was drawn using the program
SPOCK developed by JA Christopher at Texas A&M University.)
Figure 6
Stereoview superimposition of PA (cyan),
PRPCP (yellow) and NAMN (green) as
observed in QAPRTase. The NCS-averaged
difference fourier maps, (|Fo|–|Fc|)ϕc, of the
active sites of the QAPRTase–NAMN (purple)
and QAPRTase–PA–PRPCP (blue)
complexes are also shown. The maps were
calculated before addition of the NAMN or
PRPCP coordinates to the model. Maps are
contoured at the 5σ level. (The figures were
generated using the program O [29].)
known PRTase to contain an α/β-barrel domain and an
open β-sandwich domain, has most likely evolved inde-
pendently of type I PRTases. As both types of PRTase
utilize PRPP as a substrate, the PRPP-binding site pro-
vides a good starting point to analyze their functional con-
vergence. The structures of OPRTase–PRPP [10] and
GPATase–cPRPP [20] provide the two known examples
of PRPP-bound type I PRTases, and bind PRPP in a very
similar conformation to that of QAPRTase. Moreover, the
ribose sugar pucker and metal ligation is virtually con-
served even in the PRPP of QAPRTase. The superimpo-
sition of the phosphoribosyl moiety of the cPRPP in
GPATase and PRPCP in QAPRTase suggests that the
only difference in conformation of the two PRPP analogs
is an almost 60° rotation of the pyrophosphate group
around the C1–O1 bond (Figure 9). The analysis of the
residues interacting with these pyrophosphates shows that
the residues Asp222 and Glu201 in QAPRTase are remi-
niscent of the conserved dipeptide (Asp366–Asp367 in
GPATase) of type I PRTases. These residues are oriented
in a similar fashion in the two structures but are shifted by
2–3 Å in consonance with the alternate conformation of
the pyrophosphate (Figure 9). Arg48′ of QAPRTase is the
only other residue having a counterpart (Arg332) in
GPATase, both interacting with the β phosphates. Thus,
despite vast structural differences between the two classes
of PRTase, there appears to be a common theme in the
design of their active sites.
Mechanism of the QAPRTase reaction
Steady-state kinetic studies on Escherichia coli QAPRTase
suggested an ordered sequential mechanism in which
PRPP binds first to the enzyme followed by QA to form
the active ternary complex [24]. However, our recent
isotope partitioning studies on St-QAPRTase and
Mt-QAPRTase suggest that the sequence of binding is
ordered, but with PRPP following QA (Hong Cao, per-
sonal communication). The crystal structure of the ternary
complex further supports our hypothesis, as QA is buried
much deeper in the active site than PRPP, which is closer
to the surface. Moreover, comparison of the apo,
QAPRTase–QA and QAPRTase–PA–PRPP complexes
suggests that QA assists the binding of PRPP by inducing
favorable conformational changes in the active-site
residues, as described above. Such favorable enzyme–QA
interactions can help offset an unfavorable binding of
PRPP to the enzyme–QA complex — an energetic trade-
off first proposed by Jencks [26].
Phosphoribosyl transfer has been proposed to proceed via
a unimolecular nucleophilic substitution (SN1 reaction)
involving an oxycarbonium-like intermediate [11]. In a
rate-limiting step, the pyrophosphate group of PRPP is
protonated and cleaved to yield an oxycarbonium of ribo-
sylphosphate. The formation of the anticipated interme-
diate may be facilitated by the electron-withdrawing power
of the metal ions and the C3-exo pucker of the ribosyl
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Figure 8
Schematic diagram of the QAPRTase
interactions with QA and PRPP. (The figure
was drawn using the program Chemdraw Plus
version 3.1 [Cambridge Scientific
Computing].)
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Structure
ring, as proposed for type I PRTases [20]. Subsequently,
the nucleophilic N1 of QA combines with the oxycarbo-
nium in a diffusion-controlled reaction to form quinolinic
acid mononucleotide (QAMN). Large positive electrostatic
potential due to the sidechain of Lys140 is likely to guide
the movement of the oxycarbonium intermediate by repul-
sion of the positively charged C1–O4 bond. The decar-
boxylation of QAMN, either enzymatic or spontaneous,
would finally lead to the formation of NAMN. A transition-
state structure with a high degree of oxycarbonium charac-
ter has been implicated in the reaction catalyzed by
OPRTase [11]. A similar reactive intermediate formed in
the QAPRTase reaction would not only have to be stabi-
lized by negatively charged residues but would also have to
be shielded from the bulk solvent. Indeed, the structure
supports residues Glu201 and Asp222 as likely candidates
for the stabilization of the positively charged transition
state. The carboxylate sidechain of Glu201 may also carry
out the deprotonation of the 2-hydroxyl group required for
activation of the ribose. Residues Lys140 and Arg105′ may
participate in the stabilization of the excess negative
charge on the leaving pyrophosphate. In addition to the
favorable positions of these protein residues, the oxycarbo-
nium intermediate seems to be shielded from the bulk
solvent by the leaving pyrophosphate group. 
A major goal of our work on Mt-QAPRTase is to utilize
the three-dimensional structure of this enzyme to initiate
a directed effort towards identifying novel antitubercular
compounds. Knowledge of the design of the QAPRTase
active site and of the substrate-induced conformational
changes can be exploited in designing novel inhibitors for
the enzyme. In addition, the structures of the QAPRTase–
PRPCP and QAPRTase–NAMN complexes provide a
more complete understanding of the mechanism of ribose-
phosphate transfer in Mt-QAPRTase. Subtle differences
between the active sites of the mycobacterial and human
enzymes (Figure 3) — in the QA-binding site (Leu170→
Met) or PRPP-binding site (Arg48→Lys, Ala268→Ser,
Ala271→Met and His274→Gln) — could be exploited in
the design of drugs specific for mycobacteria. The design
of QA analogs that could engage the conformational plas-
ticity of the active site by locking it in a more apo-like
structure, thereby preventing PRPP binding and the sub-
sequent reaction, may prove to be good inhibitors. Such
inhibitors may be further evolved into bifunctional com-
pounds by the addition of a group resembling PRPP,
using the constraints from the ternary complex model.
The efficacy of such compounds can be tested readily,
using purified recombinant protein as well as recombi-
nant clones in nadC-deficient E. coli.
Biological implications
Mycobacterium tuberculosis infection is estimated to occur
in one-third of the world’s population. The emergence of
drug-resistant tuberculosis (TB) strains and the correla-
tion of TB with infection by the human immunodefi-
ciency virus (HIV) has resulted in a world-wide TB
epidemic. The recent elucidation of the mechanism of
action of isoniazid, a frontline anti-TB drug, has  revealed
the vulnerability of NAD metabolism in tubercle bacilli.
Manipulation of NADH/NAD+ levels has been shown
to confer isoniazid resistance. The absence of an active
salvage pathway for the biosynthesis of NAD in
M. tuberculosis further limits its means to replenish the
much needed cofactor. 
Quinolinic acid phosphoribosyltransferase (QAPRTase),
an essential enzyme for the de novo biosynthesis of NAD,
catalyzes the formation of nicotinic acid mononucleotide
(NAMN) from quinolinic acid (QA) and phosphoribosyl
pyrophosphate (PRPP). QAPRTase belongs to the
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Figure 9
Superimposition of PRPCP in QAPRTase
(blue) and cPRPP in GPATase (yellow). (The
figure was drawn using the program SPOCK
developed by JA Christopher at Texas A&M
University.)
phosphoribosyltransferase (PRTase) family of enzymes,
all of which utilize PRPP as a substrate. Most known
PRTases possess a type I fold consisting of five β strands
surrounded by four α helices. QAPRTase, the only
known type II structure, consists of an N-terminal four-
stranded antiparallel open β-sandwich domain and a
C-terminal seven-stranded α/β-barrel domain. The
different architecture observed for the two types of
PRTase suggests their evolution from discrete ances-
tors. Moreover, QAPRTase lacks the conserved PRPP-
binding motif of type I PRTases, indicating an alternate
PRPP-binding site for type II enzymes. The structure of
the ternary complex of QAPRTase with bound sub-
strate analogs — phthalic acid (PA) and 5-phosphoribo-
syl-1-(β-methylene)pyrophosphate (PRPCP) — describe
s the PRPP interactions for such a type II binding site.
Comparison of the PRPP-binding sites in the two types
of PRTase provides a structural perspective of the
convergence of two protein folds to a similar reaction
mechanism.
This study reveals that QAPRTase has two conformers:
a relaxed conformer, observed in the structures of the
apoenzyme and its complex with NAMN, and an active
conformer, seen in its complex with the substrate QA or
inhibitor PA and in a nonproductive ternary complex
with PA and PRPCP. Structural changes accompany-
ing the transition between the two conformers appear to
be critical in determining substrate specificity, in eliciting
productive catalysis, and in ensuring product release.
The binding of QA is necessary and sufficient to induce
these conformational changes. A sequential order of
substrate binding prevents any wasteful lysis of PRPP
by the enzyme.
Materials and methods
Materials
General reagents, buffers and NAMN were obtained from Sigma.
Luria broth (LB) media was from Difco. Enzymes and reagents for
molecular biology were from New England Biolabs, Boehringer
Mannheim and GIBCO-BRL. Plasmid pET(30b) and E. coli BL21(DE3)
competent cells were obtained from Novagen. Polyethylene glycol
(PEG) 4000, PA and QA were from Fluka. Plasmid purification kits
were supplied by QIAGEN. Oligonucleotides were synthesized by
the Gene Technology Laboratory at Texas A&M University. M. tuber-
culosis strain H37Rv genomic DNA was supplied by JT Belisle at Col-
orado State University under NIH-AIDS Research and Reference
Program. PRPCP was synthesized in the laboratory of C Grubmeyer
at Temple University.
Cloning, expression and purification
The gene nadC encoding QAPRTase in M. tuberculosis was identified
in the sequences available at the mycobacterium genome sequence
database (MycDB). Primers corresponding to the N and C termini of
the QAPRTase were designed and used to amplify the corresponding
DNA using M. tuberculosis genomic DNA as a template. The poly-
merase chain reaction (PCR) product was cut with restriction enzymes
NdeI and HindIII and cloned into the same sites in the plasmid
pET(30b). QAPRTase was overexpressed in E. coli strain BL21(DE3).
The bacterial cells were lysed and the enzyme purified to homogeneity
using a combination of Q-sepharose ion exchange, S-75 gel filtration
and phenyl-sepharose hydrophobic interaction chromatography. The
purified protein was stored as a precipitate in 85% saturated ammo-
nium sulfate solution.
Crystallization
Initial crystallization conditions were obtained using Crystal Screen I
from Hampton Research. Crystals were grown by hanging-drop vapor
diffusion at 16°C using 25–30% PEG 4000, 0.2 M (NH4)2SO4 and
0.1 M Tris pH 8.0. The crystals were hexagonal, space group P31, with
unit-cell dimensions of a = b = 100.58 Å, c = 144.45 Å, α = β = 90°
and γ = 120°. An estimation of 45% solvent content indicated the pres-
ence of six monomers of QAPRTase in an asymmetric unit. Three
heavy-atom derivatives were obtained by soaking crystals in mercury
acetate, samarium chloride and sodium hexachloroplatinate solutions
each at 10 mM final concentration.
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Table 2
Summary of final statistics*.
Native QA PA NAMN PA–PRPCP
Resolution (Å) 8.0–2.4 8.0–2.45 8.0–2.5 8.0–2.6 8.0–2.45
Unique reflections 68,930 55,485 58,672 48,262 58,603
Redundancy 2.82 3.55 3.46 2.98 4.63
Completeness (%) 94.9 97.8 97.8 96.3 96.9
Rsym (%) 7.6 6.1 7.4 7.5 7.9
R factor (%)† 17.6 17.8 18.0 18.5 18.6
Rfree(%)‡ 24.2 25.3 25.0 26.9 25.1
Water molecules 284 266 260 263 303
Rmsd
bond lengths (°) 0.013 0.013 0.013 0.014 0.017
bond angles (Å) 1.796 1.826 1.817 1.887 1.834
Average B factors (Å2) 25.7 27.0 24.6 30.7 27.1
*Data were collected at room temperature and a single crystal was used for each of the refined structures. †R factor = (Σ|Fobs–Fcalc|)/ΣFobs, where Fobs
is the observed structure factor and Fcalc is the structure factor calculated from the final model. ‡Rfree is the R factor calculated for a random 10%
subset of the reflection data.
Data collection and processing
X-ray intensity data were collected at room temperature using Mac-
Science automated dual image plate system on a Rigaku RU200,
equipped with mirrors. The data were processed with the DENZO and
SCALEPACK software packages [27]. The structure was solved by mul-
tiple isomorphous replacement (MIR) using three heavy-atom derivatives.
For each derivative, six distinct heavy-atom sites were obtained from
cross-inspection of isomorphous difference Patterson maps and differ-
ence Fourier maps obtained from trial protein phases. The parameters of
all heavy-atom derivatives were refined and MIR phases were calculated
with the program PHASES [28] using intensity data from 10.0–2.8 Å res-
olution. Protein phases were calculated to 2.8 Å resolution and the figure
of merit improved by solvent flattening to 0.55. The resulting electron-
density maps were not clear, however, the boundaries of the three dimers
in the asymmetric unit related by a threefold NCS could be very well iden-
tified. One cycle of NCS averaging (PHASES) of the electron density
was undertaken, using manually edited solvent masks and the NCS
matrix calculated from the heavy-atom positions. The resulting phases at
2.8 Å resolution had a figure of merit of 0.7 and yielded an interpretable
electron density to which a polyalanine model was fit using the program
O [29]. An extensive series of ‘phase-combined’ maps were used to
build the initial model which consisted of residues 2–285 of each subunit
and had an initial R factor of 46.5% to 2.8 Å resolution. The model was
refined by molecular dynamics and energy minimization (using the
program X-PLOR [30]) with noncrystallographic restraints using data to
2.8 Å, which dropped the R factor to 28.6%. Successive cycles of
manual model rebuilding, energy minimization and simulated-annealing
refinement using X-PLOR were employed. During the later cycles, NCS
restraints were relaxed, the B factor was refined and the resolution was
extended to 2.4 Å. Solvent atoms were added to the model at positions
of well defined electron density (at least 3σ) in the (|Fo–Fc|)φc difference
map, and where hydrogen-bonding partners were available within 3.3 Å.
The final model consisted of residues 2–285 of each subunit, six sulfate
ions and 276 water molecules; the model was refined to a final R factor
of 18.2% and Rfree of 25.0%. The current model displays excellent stere-
ochemistry as determined by PROCHECK [31]. A summary of the final
statistics is given in Table 2.
The QAPRTase complexes
Crystals soaked for one to two days in a 2 mM solution of either QA, PA
or NAMN prior to data collection revealed clear density in (|FQA|–|FAPO|)fc
difference maps. The QAPRTase–PA–PRPCP complex was obtained by
growing the crystals in crystallization buffer containing an additional
5 mM each of PA, PRPCP and MnCl2 and soaked overnight in the same
solution prior to the data collection. For the structures with bound
ligands, the refined apo QAPRTase coordinates were subjected to rigid-
body refinement and simulated-annealing refinement using X-PLOR. Sim-
ulated annealing omit maps and (2|Fo|–|Fc|)fc were used to rebuild the
area around the active site. Difference maps obtained after energy mini-
mization and B-factor refinement showed clear density for the ligands.
Sixfold NCS averaging (CCP4 [32]) of the difference maps using a man-
ually edited mask further improved the density for the NAMN-bound and
PRPCP–PA-bound complexes. The ligand and solvent molecules were
then added to the model and further model building, energy minimization
and B-factor refinement reduced the R factors.
Accession numbers
The coordinates have been deposited in the Brookhaven Protein Data
Bank with accession code 1QPR. 
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